首页 > 最新文献

Journal of Lower Genital Tract Disease最新文献

英文 中文
ASCCP Clinical Guidance Document Standardization. ASCCP临床指导文件标准化。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-07-01 Epub Date: 2025-04-22 DOI: 10.1097/LGT.0000000000000896
Jenna Z Marcus, Christine Conageski, Akiva P Novetsky, David P Chelmow

Abstract: The American Society for Colposcopy and Cervical Pathology (ASCCP) provides practice guidance for clinicians caring for patients with lower genital tract conditions. The ASCCP wants to ensure that its library of guidance documents is current, evidence based, and easy for clinicians to use. Guidance documents should present clear, actionable evidence-based management recommendations where the quality of the evidence and the strength of the recommendation are clearly identified. This document explains ASCCP's new standard document types and the processes for their development and maintenance, as well as the process for selecting new topics.

摘要:美国阴道镜与宫颈病理学会(ASCCP)为临床医生护理下生殖道疾病患者提供实践指导。ASCCP希望确保其指导文件库是最新的、基于证据的,并且便于临床医生使用。指导文件应提出明确的、可操作的循证管理建议,其中应明确确定证据的质量和建议的力度。本文档解释了ASCCP的新标准文档类型及其开发和维护过程,以及选择新主题的过程。
{"title":"ASCCP Clinical Guidance Document Standardization.","authors":"Jenna Z Marcus, Christine Conageski, Akiva P Novetsky, David P Chelmow","doi":"10.1097/LGT.0000000000000896","DOIUrl":"10.1097/LGT.0000000000000896","url":null,"abstract":"<p><strong>Abstract: </strong>The American Society for Colposcopy and Cervical Pathology (ASCCP) provides practice guidance for clinicians caring for patients with lower genital tract conditions. The ASCCP wants to ensure that its library of guidance documents is current, evidence based, and easy for clinicians to use. Guidance documents should present clear, actionable evidence-based management recommendations where the quality of the evidence and the strength of the recommendation are clearly identified. This document explains ASCCP's new standard document types and the processes for their development and maintenance, as well as the process for selecting new topics.</p>","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"263-268"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-Collected Swabs for Primary HPV Screening in an Underscreened Population in Hawaii. 自我收集拭子用于夏威夷未筛查人群的初级HPV筛查。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-07-01 Epub Date: 2025-04-10 DOI: 10.1097/LGT.0000000000000887
Anna Ung, Jonathan Riel, Paris Stowers, Jeffrey Killeen, Singne Brown, Ann Chang

Objectives: This study assessed the feasibility and acceptability of Human Papillomavirus (HPV) self-swab collection at a Hawaii-based Federally Qualified Health Center in the United States with low cervical cancer screening rates.

Methods: Patients with an indication for cervical cancer screening were approached during their scheduled primary care visit. Consenting participants self-collected a sample for primary HPV testing. After sample collection, participants completed a 5-minute written survey concerning their experience collecting the sample and knowledge of cervical cancer.

Results: From August 2023 through May 2024, 20 participants enrolled and completed the study, including 5 participants who had never undergone any prior cervical cancer screening and 7 participants over the age of 65. The HPV analysis confirmed 1 positive result. Most (17 of 20) of the participants described the self-collection process as very easy or easy. Knowledge of HPV and cervical cancer prevalence was low with only 2 of 20 participants (10%) correctly identifying the prevalence of these conditions.

Conclusions: Self-swab screening for HPV is feasible with high patient satisfaction in the studied population.

目的:本研究评估了人类乳头瘤病毒(HPV)自拭子采集在位于夏威夷的美国联邦合格健康中心的可行性和可接受性,该中心的宫颈癌筛查率较低。方法:有宫颈癌筛查指征的患者在其预定的初级保健访问期间进行接触。同意的参与者自行收集样本进行原发性HPV检测。样本收集后,参与者完成了一项5分钟的书面调查,内容涉及他们收集样本的经验和对宫颈癌的了解。结果:从2023年8月到2024年5月,20名参与者入组并完成了研究,其中5名参与者从未接受过任何宫颈癌筛查,7名参与者年龄在65岁以上。HPV分析证实1例阳性。大多数参与者(20人中有17人)认为自我收集过程非常容易或容易。对HPV和宫颈癌患病率的了解很低,20名参与者中只有2名(10%)正确认识到这些疾病的患病率。结论:在研究人群中,自拭子HPV筛查是可行的,患者满意度高。
{"title":"Self-Collected Swabs for Primary HPV Screening in an Underscreened Population in Hawaii.","authors":"Anna Ung, Jonathan Riel, Paris Stowers, Jeffrey Killeen, Singne Brown, Ann Chang","doi":"10.1097/LGT.0000000000000887","DOIUrl":"10.1097/LGT.0000000000000887","url":null,"abstract":"<p><strong>Objectives: </strong>This study assessed the feasibility and acceptability of Human Papillomavirus (HPV) self-swab collection at a Hawaii-based Federally Qualified Health Center in the United States with low cervical cancer screening rates.</p><p><strong>Methods: </strong>Patients with an indication for cervical cancer screening were approached during their scheduled primary care visit. Consenting participants self-collected a sample for primary HPV testing. After sample collection, participants completed a 5-minute written survey concerning their experience collecting the sample and knowledge of cervical cancer.</p><p><strong>Results: </strong>From August 2023 through May 2024, 20 participants enrolled and completed the study, including 5 participants who had never undergone any prior cervical cancer screening and 7 participants over the age of 65. The HPV analysis confirmed 1 positive result. Most (17 of 20) of the participants described the self-collection process as very easy or easy. Knowledge of HPV and cervical cancer prevalence was low with only 2 of 20 participants (10%) correctly identifying the prevalence of these conditions.</p><p><strong>Conclusions: </strong>Self-swab screening for HPV is feasible with high patient satisfaction in the studied population.</p>","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"213-217"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12188802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges With Diagnosis of Labial Agglutination Due to Lichen Sclerosus. 硬苔性唇粘连诊断的挑战。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-07-01 Epub Date: 2025-02-10 DOI: 10.1097/LGT.0000000000000874
Esha Ghosalkar, Samantha Epstein, Allison Epstein, Melissa Mauskar, Rachel Pope

Objective: Labial adhesion (LA) lacks a clear etiology but is associated with low estrogen levels and lichen sclerosus (LS). Genitourinary Syndrome of Menopause is a contributor due to low estrogen, needing surgical resection if symptoms persist after topical estrogen use. Early diagnosis and treatment of LS can decrease the risk of development of LA. The objective is to investigate LS prevalence as an etiological factor and evaluate the necessity for enhanced biopsy rates in LA patients.

Methods: TrinetX provided data from 80 global health care centers, focusing on patients with LA using ICD-10-CM coding. The cohort was stratified based on vulva surgery 2 years post-LA diagnosis to establish a causal relationship.

Results: A total of 11,875 women over the age of 18 were diagnosed with LA from 2000 to 2023. Of those, 3,673 (30.93%) underwent a surgical procedure on the female genital system within 2 years. Demographic data included a mean age of 45 years, 67.9% identified as White, 6.53% as Black/African American, 20.52% unknown, and 2.45% other races. Of the 3,673 total women, 11% had a documented biopsy prior to or with the surgery, leading to 11% (395 women) being diagnosed with LS. Limitations include inconsistent medical coding, uncertain causality between conditions, and potential data inconsistencies from the national database.

Conclusions: Labial adhesion has a complex etiology, yet is associated with LS, emphasizing the need for biopsy in management when the first-line estrogen cream approach fails. Future studies on LA etiologies can improve approaches to female sexual health care disorders, enhancing patient care.

目的:唇粘连(LA)缺乏明确的病因,但与雌激素水平低和硬化地衣(LS)有关。绝经期泌尿生殖系统综合征是雌激素水平低的一个因素,如果局部使用雌激素后症状仍然存在,则需要手术切除。LS的早期诊断和治疗可以降低LA的发生风险。目的是调查LS患病率作为一个病因因素,并评估在LA患者中提高活检率的必要性。方法:TrinetX提供了来自全球80个卫生保健中心的数据,重点关注使用ICD-10-CM编码的LA患者。该队列根据la诊断后2年的外阴手术进行分层,以建立因果关系。结果:从2000年到2023年,共有11,875名18岁以上的女性被诊断为LA。其中,3,673人(30.93%)在2年内接受了女性生殖系统手术。人口统计数据包括平均年龄45岁,67.9%为白人,6.53%为黑人/非裔美国人,20.52%为未知种族,2.45%为其他种族。在3673名女性中,11%的人在手术前或手术中进行了活检,导致11%(395名女性)被诊断为LS。限制包括不一致的医疗编码、不确定的病症之间的因果关系以及来自国家数据库的潜在数据不一致。结论:唇粘连具有复杂的病因,但与LS相关,强调了当一线雌激素乳膏方法失败时,需要进行活检。未来对LA病因的研究可以改善女性性健康保健障碍的方法,加强患者护理。
{"title":"Challenges With Diagnosis of Labial Agglutination Due to Lichen Sclerosus.","authors":"Esha Ghosalkar, Samantha Epstein, Allison Epstein, Melissa Mauskar, Rachel Pope","doi":"10.1097/LGT.0000000000000874","DOIUrl":"10.1097/LGT.0000000000000874","url":null,"abstract":"<p><strong>Objective: </strong>Labial adhesion (LA) lacks a clear etiology but is associated with low estrogen levels and lichen sclerosus (LS). Genitourinary Syndrome of Menopause is a contributor due to low estrogen, needing surgical resection if symptoms persist after topical estrogen use. Early diagnosis and treatment of LS can decrease the risk of development of LA. The objective is to investigate LS prevalence as an etiological factor and evaluate the necessity for enhanced biopsy rates in LA patients.</p><p><strong>Methods: </strong>TrinetX provided data from 80 global health care centers, focusing on patients with LA using ICD-10-CM coding. The cohort was stratified based on vulva surgery 2 years post-LA diagnosis to establish a causal relationship.</p><p><strong>Results: </strong>A total of 11,875 women over the age of 18 were diagnosed with LA from 2000 to 2023. Of those, 3,673 (30.93%) underwent a surgical procedure on the female genital system within 2 years. Demographic data included a mean age of 45 years, 67.9% identified as White, 6.53% as Black/African American, 20.52% unknown, and 2.45% other races. Of the 3,673 total women, 11% had a documented biopsy prior to or with the surgery, leading to 11% (395 women) being diagnosed with LS. Limitations include inconsistent medical coding, uncertain causality between conditions, and potential data inconsistencies from the national database.</p><p><strong>Conclusions: </strong>Labial adhesion has a complex etiology, yet is associated with LS, emphasizing the need for biopsy in management when the first-line estrogen cream approach fails. Future studies on LA etiologies can improve approaches to female sexual health care disorders, enhancing patient care.</p>","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"269-272"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143392343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis to Excision: Estimates for Guideline-Concordant Treatment of High-Grade Cervical Intraepithelial Neoplasia. 从诊断到切除:高级别宫颈上皮内瘤变的指南一致性治疗评估。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-07-01 Epub Date: 2025-03-18 DOI: 10.1097/LGT.0000000000000880
Nerlyne Desravines, Michael R Desjardins, J Stuart Ferriss, Jamie Perrin, Lisa Rahangdale

Objective: To estimate the proportion of participants with high-grade cervical intraepithelial neoplasia (CIN 2/3) who completed indicated therapeutic procedures.

Methods: This was a retrospective observational cohort study of the National Institutes of Health's All of Us database enriched for racial and ethnic minorities historically underrepresented in biomedical research. The study included female participants aged 25 and older with a diagnosis of CIN 2/3 only, excluding invasive malignancy. The authors conducted both univariate and multivariate logistic regression to identify background characteristics associated with guideline-concordant ablative and excisional procedures.

Results: Of 1,764 participants with CIN 2/3, only 27.7% of participants underwent a therapeutic procedure in the 12 months following a diagnosis of CIN 2/3. The study found that Hispanic participants had a 1.48 increased odds ratio (OR) (95% CI = 1.18-1.85) of undergoing therapeutic procedures (compared to non-Hispanic). Participants residing in the Midwest had a 2.04 OR (95% CI = 1.6-2.6) of undergoing a therapeutic procedure compared to the Northeast. After adjustment for race, ethnicity, region, and smoking status, Hispanic ethnicity remained associated with therapeutic excision (OR = 2.37, 1.13-4.78). Geography was significant with 2.37 (95% CI = 1.17-3.29) increased odds of therapy completions for Midwest residents but 0.52 (95% CI = 0.27-0.96) decreased odds for Western residents.

Conclusion: In this large US national database enriched for racial and ethnic minorities, the authors found that 3 of 4 participants with cervical precancer did not undergo a therapeutic procedure in the 12 months following their first diagnosis. Increased efforts to promote access to and completion of treatment of CIN 2/3 are needed to prevent cancer.

目的:估计完成指示治疗程序的高级别宫颈上皮内瘤变(CIN 2/3)参与者的比例。方法:这是一项回顾性观察队列研究,来自美国国立卫生研究院的All of Us数据库,该数据库丰富了历史上在生物医学研究中代表性不足的种族和少数民族。我们纳入了年龄在25岁及以上且仅诊断为CIN 2/3的女性参与者,排除了侵袭性恶性肿瘤。我们进行了单变量和多变量逻辑回归,以确定与指南一致的消融和切除手术相关的背景特征。结果:在1764名CIN 2/3的参与者中,只有27.7%的参与者在诊断CIN 2/3后的12个月内接受了治疗。我们发现,与非西班牙裔患者相比,西班牙裔患者接受治疗的优势比(OR) (95% CI = 1.18-1.85)增加了1.48。与东北地区相比,居住在中西部地区的参与者接受治疗的OR为2.04 (95% CI = 1.6-2.6)。在调整了种族、民族、地区和吸烟状况后,西班牙裔仍与治疗性切除相关(OR = 2.37, 1.13-4.78)。地域差异显著,中西部居民治疗完成率增加2.37 (95% CI = 1.17-3.29),西部居民治疗完成率减少0.52 (95% CI = 0.27-0.96)。结论:在这个丰富了种族和少数民族的大型美国国家数据库中,我们发现4名宫颈癌前病变患者中有3名在首次诊断后的12个月内没有接受治疗。需要加大努力,促进获得和完成CIN 2/3的治疗,以预防癌症。
{"title":"Diagnosis to Excision: Estimates for Guideline-Concordant Treatment of High-Grade Cervical Intraepithelial Neoplasia.","authors":"Nerlyne Desravines, Michael R Desjardins, J Stuart Ferriss, Jamie Perrin, Lisa Rahangdale","doi":"10.1097/LGT.0000000000000880","DOIUrl":"10.1097/LGT.0000000000000880","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the proportion of participants with high-grade cervical intraepithelial neoplasia (CIN 2/3) who completed indicated therapeutic procedures.</p><p><strong>Methods: </strong>This was a retrospective observational cohort study of the National Institutes of Health's All of Us database enriched for racial and ethnic minorities historically underrepresented in biomedical research. The study included female participants aged 25 and older with a diagnosis of CIN 2/3 only, excluding invasive malignancy. The authors conducted both univariate and multivariate logistic regression to identify background characteristics associated with guideline-concordant ablative and excisional procedures.</p><p><strong>Results: </strong>Of 1,764 participants with CIN 2/3, only 27.7% of participants underwent a therapeutic procedure in the 12 months following a diagnosis of CIN 2/3. The study found that Hispanic participants had a 1.48 increased odds ratio (OR) (95% CI = 1.18-1.85) of undergoing therapeutic procedures (compared to non-Hispanic). Participants residing in the Midwest had a 2.04 OR (95% CI = 1.6-2.6) of undergoing a therapeutic procedure compared to the Northeast. After adjustment for race, ethnicity, region, and smoking status, Hispanic ethnicity remained associated with therapeutic excision (OR = 2.37, 1.13-4.78). Geography was significant with 2.37 (95% CI = 1.17-3.29) increased odds of therapy completions for Midwest residents but 0.52 (95% CI = 0.27-0.96) decreased odds for Western residents.</p><p><strong>Conclusion: </strong>In this large US national database enriched for racial and ethnic minorities, the authors found that 3 of 4 participants with cervical precancer did not undergo a therapeutic procedure in the 12 months following their first diagnosis. Increased efforts to promote access to and completion of treatment of CIN 2/3 are needed to prevent cancer.</p>","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"243-250"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143659296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Awards Presented as Part of the ASCCP 2025 Scientific Meeting on Anogenital & HPV-Related Diseases. 作为ASCCP 2025年肛门生殖器和hpv相关疾病科学会议的一部分颁发的奖项。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-04-30 DOI: 10.1097/LGT.0000000000000897
{"title":"Awards Presented as Part of the ASCCP 2025 Scientific Meeting on Anogenital & HPV-Related Diseases.","authors":"","doi":"10.1097/LGT.0000000000000897","DOIUrl":"https://doi.org/10.1097/LGT.0000000000000897","url":null,"abstract":"","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor Regarding "A Narrative Review of the Vulvar Disease Literature With Images of Women of Color". 关于“外阴疾病文学与有色人种女性形象的叙事回顾”的致编辑信。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-17 DOI: 10.1097/LGT.0000000000000872
Debra S Heller
{"title":"Letter to the Editor Regarding \"A Narrative Review of the Vulvar Disease Literature With Images of Women of Color\".","authors":"Debra S Heller","doi":"10.1097/LGT.0000000000000872","DOIUrl":"10.1097/LGT.0000000000000872","url":null,"abstract":"","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"204"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143015407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Self-Collected Vaginal Specimens for HPV Testing: Recommendations From the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee. 自收集阴道标本用于HPV检测:持久共识宫颈癌筛查和管理指南委员会的建议。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-04-01 Epub Date: 2025-02-21 DOI: 10.1097/LGT.0000000000000885
Nicolas Wentzensen, L Stewart Massad, Megan A Clarke, Francisco Garcia, Robert Smith, Jeanne Murphy, Richard Guido, Ana Reyes, Sarah Phillips, Nancy Berman, Jeffrey Quinlan, Eileen Lind, Rebecca B Perkins

Objective: The Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee developed recommendations for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing in health care settings.

Methods: A comprehensive literature search was performed, external systematic reviews were evaluated, and HPV genotype agreement between self-collected vaginal and clinician-collected cervical specimens was summarized. Recommendations considered available data, public comments, and expert consensus. Recommendations were ratified through a vote by the Consensus Stakeholder Group.

Results: Clinician-collected cervical specimens are preferred and self-collected vaginal specimens are acceptable for primary HPV screening of asymptomatic average-risk individuals. Repeat testing in 3 years is recommended following HPV-negative screens using self-collected vaginal specimens. Colposcopy with collection of cytology and biopsies is recommended following positive tests for HPV types 16 and 18. Clinician-collected cytology or dual stain for triage testing is recommended following positive tests for HPV 45, 33/58, 31, 52, 35/39/68, or 51 or for pooled HPV other types but negative for HPV 16 or 18. Repeat HPV testing in 1 year is recommended following a positive test for HPV types 56/59/66 and no other carcinogenic types. Minimal data exist on use of self-collected vaginal specimens for surveillance following abnormal screening test results, colposcopy or treatment, and therefore, clinician-collected cervical specimens are preferred.

Conclusions: Human papillomavirus testing of self-collected vaginal specimens expands cervical cancer screening options and has potential to increase access for currently underscreened individuals. Laboratory and clinical workflows will need to be modified to ensure adequate specimen processing and follow-up.

目的:持久共识宫颈癌筛查和管理指南委员会制定了在卫生保健机构中使用自行收集的阴道标本进行人乳头瘤病毒(HPV)检测的建议。方法:进行全面的文献检索,进行外部系统评价,总结自采阴道和临床采集宫颈标本间HPV基因型的一致性。建议考虑了现有数据、公众意见和专家共识。建议由协商一致利益攸关方小组投票批准。结果:临床采集的宫颈标本是首选,自行采集的阴道标本可用于无症状平均风险个体的原发性HPV筛查。建议在使用自行收集的阴道标本进行hpv阴性筛查后3年内重复检测。在HPV 16型和18型检测呈阳性后,建议进行阴道镜检查并收集细胞学和活检。在HPV 45、33/58、31、52、35/39/68或51检测呈阳性,或HPV 16或18检测呈阴性后,建议采用临床收集的细胞学检查或双染色进行分类检测。如果56/59/66型HPV检测呈阳性,且没有其他致癌类型,建议在1年内重复HPV检测。很少有数据表明,在筛查结果异常、阴道镜检查或治疗后,使用自行采集的阴道标本进行监测,因此,临床采集的宫颈标本是首选。结论:对自己收集的阴道标本进行人乳头瘤病毒检测,扩大了宫颈癌筛查的选择范围,并有可能增加目前未接受筛查的个体获得筛查的机会。需要修改实验室和临床工作流程,以确保充分的标本处理和随访。
{"title":"Self-Collected Vaginal Specimens for HPV Testing: Recommendations From the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee.","authors":"Nicolas Wentzensen, L Stewart Massad, Megan A Clarke, Francisco Garcia, Robert Smith, Jeanne Murphy, Richard Guido, Ana Reyes, Sarah Phillips, Nancy Berman, Jeffrey Quinlan, Eileen Lind, Rebecca B Perkins","doi":"10.1097/LGT.0000000000000885","DOIUrl":"10.1097/LGT.0000000000000885","url":null,"abstract":"<p><strong>Objective: </strong>The Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee developed recommendations for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing in health care settings.</p><p><strong>Methods: </strong>A comprehensive literature search was performed, external systematic reviews were evaluated, and HPV genotype agreement between self-collected vaginal and clinician-collected cervical specimens was summarized. Recommendations considered available data, public comments, and expert consensus. Recommendations were ratified through a vote by the Consensus Stakeholder Group.</p><p><strong>Results: </strong>Clinician-collected cervical specimens are preferred and self-collected vaginal specimens are acceptable for primary HPV screening of asymptomatic average-risk individuals. Repeat testing in 3 years is recommended following HPV-negative screens using self-collected vaginal specimens. Colposcopy with collection of cytology and biopsies is recommended following positive tests for HPV types 16 and 18. Clinician-collected cytology or dual stain for triage testing is recommended following positive tests for HPV 45, 33/58, 31, 52, 35/39/68, or 51 or for pooled HPV other types but negative for HPV 16 or 18. Repeat HPV testing in 1 year is recommended following a positive test for HPV types 56/59/66 and no other carcinogenic types. Minimal data exist on use of self-collected vaginal specimens for surveillance following abnormal screening test results, colposcopy or treatment, and therefore, clinician-collected cervical specimens are preferred.</p><p><strong>Conclusions: </strong>Human papillomavirus testing of self-collected vaginal specimens expands cervical cancer screening options and has potential to increase access for currently underscreened individuals. Laboratory and clinical workflows will need to be modified to ensure adequate specimen processing and follow-up.</p>","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"144-152"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11939108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lichen Sclerosus in Cancer Patients. 癌症患者的硬化地衣。
IF 2.1 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-04-01 Epub Date: 2025-02-06 DOI: 10.1097/LGT.0000000000000870
Amaris N Geisler, Shivani Jain, Kara Long Roche, Deborah J Goldfrank, Alina Markova, Mario E Lacouture, Sarah J Noor

Objective: To characterize the association between cancer therapies and the development of lichen sclerosus (LS) in a case series of patients.

Methods: A retrospective chart review was performed to screen for patients who were diagnosed with LS while undergoing cancer therapy at Memorial Sloan Kettering Cancer Center between 2003 and 2019. Patients were excluded if they had been diagnosed with LS prior to starting cancer therapy. Clinical and treatment characteristics were analyzed.

Results: The final study sample included 29 female patients who developed LS in the setting of systemic cancer therapy. Median time to LS onset after cancer therapy initiation was 420 days. Primary tumor types included breast (10, 34.5%), gynecologic (8, 27.6%), gastrointestinal (5, 17.2%), cutaneous (2, 6.9%), lung (2, 6.9%), and hematologic (2, 6.9%). Cancer therapy regimens included hormonal therapy (10, 34.5%), chemoradiation (7, 24.1%), cytotoxic chemotherapy (7, 24.1%), PD-1/PD-L1 inhibitors (3, 10.3%), local radiation (1, 3.4%), and allogeneic stem cell transplant (1, 3.4%). Across all patients, the mean number of treatments for LS was 2.8. Twenty-three (79.3%) patients received the first-line therapy of ultrapotent topical steroids, but 16 (69.6%) required additional topical and systemic treatment. Limitations include retrospective design and referral bias.

Conclusions: Breast cancer was the most common primary tumor among patients in this study. The most common cancer therapy regimen was hormonal therapy. Most patients required an escalation in therapy to manage their LS. For patients undergoing cancer treatment, concomitant LS management can present unique challenges due to the biological mechanism of some anticancer therapies and the pathophysiology of LS. There is limited data to guide treatment of LS for this population. Some of the patients included in this analysis had progression of LS and recurrence of cancer while undergoing management of both conditions, necessitating close follow-up.

目的:探讨肿瘤治疗与硬化地衣(LS)发展之间的关系。方法:对2003年至2019年期间在纪念斯隆凯特琳癌症中心接受癌症治疗期间被诊断为LS的患者进行回顾性图表回顾。如果患者在开始癌症治疗前被诊断为LS,则排除在外。分析临床及治疗特点。结果:最终的研究样本包括29名在系统性癌症治疗背景下发生LS的女性患者。癌症治疗开始后到LS发作的中位时间为420天。原发肿瘤类型包括乳腺(10例,34.5%)、妇科(8例,27.6%)、胃肠道(5例,17.2%)、皮肤(2例,6.9%)、肺部(2例,6.9%)和血液(2例,6.9%)。癌症治疗方案包括激素治疗(10.34.5%)、放化疗(7.24.1%)、细胞毒性化疗(7.24.1%)、PD-1/PD-L1抑制剂(3.10.3%)、局部放疗(1.3.4%)和异体干细胞移植(1.3.4%)。在所有患者中,LS的平均治疗次数为2.8次。23例(79.3%)患者接受了超强效局部类固醇的一线治疗,但16例(69.6%)患者需要额外的局部和全身治疗。局限性包括回顾性设计和推荐偏倚。结论:乳腺癌是本研究中最常见的原发肿瘤。最常见的癌症治疗方案是激素治疗。大多数患者需要升级治疗来控制他们的LS。对于正在接受癌症治疗的患者,由于一些抗癌疗法的生物学机制和LS的病理生理,LS的合并管理可能会带来独特的挑战。指导这一人群LS治疗的数据有限。本分析中包括的一些患者在接受这两种情况的治疗时出现了LS的进展和癌症的复发,需要密切随访。
{"title":"Lichen Sclerosus in Cancer Patients.","authors":"Amaris N Geisler, Shivani Jain, Kara Long Roche, Deborah J Goldfrank, Alina Markova, Mario E Lacouture, Sarah J Noor","doi":"10.1097/LGT.0000000000000870","DOIUrl":"10.1097/LGT.0000000000000870","url":null,"abstract":"<p><strong>Objective: </strong>To characterize the association between cancer therapies and the development of lichen sclerosus (LS) in a case series of patients.</p><p><strong>Methods: </strong>A retrospective chart review was performed to screen for patients who were diagnosed with LS while undergoing cancer therapy at Memorial Sloan Kettering Cancer Center between 2003 and 2019. Patients were excluded if they had been diagnosed with LS prior to starting cancer therapy. Clinical and treatment characteristics were analyzed.</p><p><strong>Results: </strong>The final study sample included 29 female patients who developed LS in the setting of systemic cancer therapy. Median time to LS onset after cancer therapy initiation was 420 days. Primary tumor types included breast (10, 34.5%), gynecologic (8, 27.6%), gastrointestinal (5, 17.2%), cutaneous (2, 6.9%), lung (2, 6.9%), and hematologic (2, 6.9%). Cancer therapy regimens included hormonal therapy (10, 34.5%), chemoradiation (7, 24.1%), cytotoxic chemotherapy (7, 24.1%), PD-1/PD-L1 inhibitors (3, 10.3%), local radiation (1, 3.4%), and allogeneic stem cell transplant (1, 3.4%). Across all patients, the mean number of treatments for LS was 2.8. Twenty-three (79.3%) patients received the first-line therapy of ultrapotent topical steroids, but 16 (69.6%) required additional topical and systemic treatment. Limitations include retrospective design and referral bias.</p><p><strong>Conclusions: </strong>Breast cancer was the most common primary tumor among patients in this study. The most common cancer therapy regimen was hormonal therapy. Most patients required an escalation in therapy to manage their LS. For patients undergoing cancer treatment, concomitant LS management can present unique challenges due to the biological mechanism of some anticancer therapies and the pathophysiology of LS. There is limited data to guide treatment of LS for this population. Some of the patients included in this analysis had progression of LS and recurrence of cancer while undergoing management of both conditions, necessitating close follow-up.</p>","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"186-189"},"PeriodicalIF":2.1,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12478288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Benefits of Endocervical Curettage in Women Infected With HPV16/18. 评估宫颈内膜刮除术对感染HPV16/18的妇女的益处
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-04-01 Epub Date: 2024-12-17 DOI: 10.1097/LGT.0000000000000863
Yusha Chen, Suyu Li, Jiancui Chen, Huifeng Xue, Xiangqin Zheng, Diling Pan

Objective: This study evaluates the effectiveness of endocervical curettage (ECC) in detecting additional high-grade squamous intraepithelial lesions or worse (HSIL+) in women infected with human papillomavirus (HPV) types 16 and 18, which may be missed by biopsy alone.

Methods: A retrospective cohort study analyzed the medical records of 4,811 women referred for colposcopy due to HPV16/18 infection from January 2019 to December 2023. Patients underwent both biopsy and ECC. Statistical comparisons of various clinical factors between HSIL+ and low-grade or normal lesions were performed using χ 2 tests and logistic regression analyses, with stratified analysis to determine ECC's additional detection rate under different clinical conditions.

Results: Endocervical curettage detected an additional 6.46% of HSIL+ lesions missed by biopsy alone, with the highest rates in women with normal colposcopic impressions (23.1%), those aged 50 or older (12%), type 3 transformation zones (9.5%), and postmenopausal women (11.9%). In contrast, younger women under 30 and those with type 1 or 2 transformation zones had significantly lower detection rates (2.9%). Logistic regression indicated that older age, type 3 transformation zone, higher grade cytological results, and abnormal colposcopic impressions are significant risk factors for HSIL+ detection via ECC ( p < .001).

Conclusions: Data from this study indicate that ECC would be beneficial for women over 30 with HPV16/18 infections, particularly those with type 3 transformation zones or normal colposcopy, as it enhances HSIL+ detection. However, it offers minimal benefit for younger women or those with type 1 or 2 transformation zones.

研究目的本研究评估了宫颈内膜刮宫术(ECC)在检测感染人乳头瘤病毒(HPV)16型和18型妇女的额外高级别鳞状上皮内病变或更严重病变(HSIL+)方面的有效性:一项回顾性队列研究分析了2019年1月至2023年12月期间因感染HPV16/18而转诊进行阴道镜检查的4811名女性的病历。患者同时接受了活检和ECC检查。采用χ2检验和逻辑回归分析对HSIL+与低级别或正常病变之间的各种临床因素进行统计比较,并进行分层分析以确定ECC在不同临床条件下的额外检出率:宫颈内膜刮宫术额外检出了6.46%的单纯活检漏诊的HSIL+病变,其中阴道镜检查结果正常(23.1%)、50岁或以上(12%)、3型转化区(9.5%)和绝经后妇女(11.9%)的检出率最高。相比之下,30 岁以下的年轻女性和有 1 型或 2 型转化区的女性的检出率明显较低(2.9%)。逻辑回归表明,年龄较大、3型转化区、细胞学结果级别较高以及阴道镜检查印象异常是通过ECC检测出HSIL+的重要风险因素(p < .001):本研究的数据表明,ECC 对 30 岁以上感染 HPV16/18 的女性有益,尤其是那些有 3 型转化区或阴道镜检查正常的女性,因为它能提高 HSIL+ 的检出率。但是,它对年轻女性或有 1 型或 2 型转化区的女性的益处很小。
{"title":"Evaluating the Benefits of Endocervical Curettage in Women Infected With HPV16/18.","authors":"Yusha Chen, Suyu Li, Jiancui Chen, Huifeng Xue, Xiangqin Zheng, Diling Pan","doi":"10.1097/LGT.0000000000000863","DOIUrl":"10.1097/LGT.0000000000000863","url":null,"abstract":"<p><strong>Objective: </strong>This study evaluates the effectiveness of endocervical curettage (ECC) in detecting additional high-grade squamous intraepithelial lesions or worse (HSIL+) in women infected with human papillomavirus (HPV) types 16 and 18, which may be missed by biopsy alone.</p><p><strong>Methods: </strong>A retrospective cohort study analyzed the medical records of 4,811 women referred for colposcopy due to HPV16/18 infection from January 2019 to December 2023. Patients underwent both biopsy and ECC. Statistical comparisons of various clinical factors between HSIL+ and low-grade or normal lesions were performed using χ 2 tests and logistic regression analyses, with stratified analysis to determine ECC's additional detection rate under different clinical conditions.</p><p><strong>Results: </strong>Endocervical curettage detected an additional 6.46% of HSIL+ lesions missed by biopsy alone, with the highest rates in women with normal colposcopic impressions (23.1%), those aged 50 or older (12%), type 3 transformation zones (9.5%), and postmenopausal women (11.9%). In contrast, younger women under 30 and those with type 1 or 2 transformation zones had significantly lower detection rates (2.9%). Logistic regression indicated that older age, type 3 transformation zone, higher grade cytological results, and abnormal colposcopic impressions are significant risk factors for HSIL+ detection via ECC ( p < .001).</p><p><strong>Conclusions: </strong>Data from this study indicate that ECC would be beneficial for women over 30 with HPV16/18 infections, particularly those with type 3 transformation zones or normal colposcopy, as it enhances HSIL+ detection. However, it offers minimal benefit for younger women or those with type 1 or 2 transformation zones.</p>","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"111-117"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. 未感染HIV的免疫抑制妇女宫颈癌筛查指南的最新综述。
IF 2.4 4区 医学 Q2 OBSTETRICS & GYNECOLOGY Pub Date : 2025-04-01 Epub Date: 2025-01-13 DOI: 10.1097/LGT.0000000000000866
Anna-Barbara Moscicki, Lisa Flowers, Megan J Huchko, Margaret E Long, Kathy L MacLaughlin, Jeanne Murphy, Lisa Beth Spiryda, Caleb J Scheckel, Michael A Gold
<p><strong>Objective: </strong>The purpose of this review was to examine new evidence since the authors' 2019 guidelines for cervical cancer (CC) screening in non-HIV immunocompromised persons and to provide updated recommendations based on literature review and expert opinion. In addition, human papillomavirus (HPV) vaccine efficacy in these populations was reviewed.</p><p><strong>Methods: </strong>A literature search was performed similar to the authors' previous publication but was conducted through March 2023. Risk of CC, squamous intraepithelial lesions, and HPV infection in those living with solid organ transplant (SOT), end-stage renal disease (ESRD), hematopoietic stem cell transplant (HSCT), and autoimmune diseases (AID), specifically systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) with addition of multiple sclerosis (MS) were researched. This update also summarizes data available on newer disease-modifying therapies (DMTs) including monoclonal antibodies (MABs). The authors then made recommendations for HPV vaccine administration, and screening using either general population guidelines or increased surveillance, the latter based on following current recommendations for women living with HIV. Additionally, the literature search included antibody response to HPV vaccines and recommendations for their administration for these same conditions.</p><p><strong>Results: </strong>Based on the reviewed risks, evidence continued to support those persons living with SOT, ESRD, HSCT, and SLE, whether on immunosuppressant therapy or not, had an increased risk of HPV, squamous intraepithelial lesions, and CC whereas there was weak evidence that those persons with IBD, RA, and MS not on immunosuppressants were at risk. Data on persons using DMT/MAB were conflicting. Data showed that patients on certain immunosuppressants had lower antibody titers following HPV vaccination. There were no studies on HPV vaccine efficacy.</p><p><strong>Conclusions: </strong>Following US Center for Disease Control and Prevention HIV Cervical cancer screening (CCS) guidelines is recommended for the following: SOT, ESRD, HSCT, and SLE whether on immunosuppressants or not, and IBD, RA, and MS on immunosuppressants. Shared decision-making about increased surveillance for IBD and RA not on immunosuppressants and persons on any DMT or MAB is reasonable based on conflicting data. Human papillomavirus vaccination should not change the recommendations for increased CC surveillance. A 3-dose series of the HPV vaccine is recommended for all age-eligible patients starting at 9 years of age, with catch-up to 26 years of age. Vaccination from age 27 up to age 45 years per Advisory Committee on Immunization Practices guidelines should be considered in shared decision-making. When possible, HPV vaccine series should be initiated and completed before SOT or initiation of DMT/MAB. For HSCT, the vaccine series should be readministered alon
目的:本综述的目的是检查自2019年非hiv免疫功能低下人群宫颈癌(CC)筛查指南以来的新证据,并根据文献综述和专家意见提供最新建议。此外,人乳头瘤病毒(HPV)疫苗在这些人群中的疗效进行了综述。方法:进行文献检索,与我们之前的出版物相似,但持续到2023年3月。研究了实体器官移植(SOT)、终末期肾病(ESRD)、造血干细胞移植(HSCT)和自身免疫性疾病(AID),特别是系统性红斑狼疮(SLE)、类风湿性关节炎(RA)和炎症性肠病(IBD)合并多发性硬化症(MS)患者的CC、鳞状上皮内病变和HPV感染的风险。本更新还总结了包括单克隆抗体(mab)在内的新型疾病修饰疗法(dmt)的可用数据。然后,我们对HPV疫苗接种和筛查提出建议,使用一般人群指南或加强监测,后者基于对感染艾滋病毒的妇女的当前建议。此外,文献检索包括对HPV疫苗的抗体反应以及对这些相同条件的管理建议。结果:基于评估的风险,证据继续支持SOT、ESRD、HSCT和SLE患者,无论是否接受免疫抑制剂治疗,HPV、鳞状上皮内病变和CC的风险增加,而IBD、RA和MS患者未接受免疫抑制剂治疗的风险增加的证据不足。使用DMT/MAB的人的数据相互矛盾。数据显示,使用某些免疫抑制剂的患者在HPV疫苗接种后抗体滴度较低。没有关于HPV疫苗效力的研究。结论:以下是美国疾病控制和预防中心HIV宫颈癌筛查(CCS)指南的推荐:SOT, ESRD, HSCT和SLE,无论是否使用免疫抑制剂,IBD, RA和MS使用免疫抑制剂。基于相互矛盾的数据,共同决定增加对IBD和RA的监测,而不是对免疫抑制剂和任何DMT或MAB患者的监测是合理的。人乳头瘤病毒疫苗接种不应改变加强CC监测的建议。建议所有符合年龄条件的患者从9岁开始接种3剂系列HPV疫苗,直至26岁。应在共同决策中考虑根据免疫实践咨询委员会指南接种27岁至45岁的疫苗。在可能的情况下,HPV疫苗系列应在SOT或DMT/MAB启动之前开始并完成。对于造血干细胞移植,该系列疫苗应与其他儿童疫苗一起重新接种。
{"title":"Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection.","authors":"Anna-Barbara Moscicki, Lisa Flowers, Megan J Huchko, Margaret E Long, Kathy L MacLaughlin, Jeanne Murphy, Lisa Beth Spiryda, Caleb J Scheckel, Michael A Gold","doi":"10.1097/LGT.0000000000000866","DOIUrl":"10.1097/LGT.0000000000000866","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;The purpose of this review was to examine new evidence since the authors' 2019 guidelines for cervical cancer (CC) screening in non-HIV immunocompromised persons and to provide updated recommendations based on literature review and expert opinion. In addition, human papillomavirus (HPV) vaccine efficacy in these populations was reviewed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A literature search was performed similar to the authors' previous publication but was conducted through March 2023. Risk of CC, squamous intraepithelial lesions, and HPV infection in those living with solid organ transplant (SOT), end-stage renal disease (ESRD), hematopoietic stem cell transplant (HSCT), and autoimmune diseases (AID), specifically systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) with addition of multiple sclerosis (MS) were researched. This update also summarizes data available on newer disease-modifying therapies (DMTs) including monoclonal antibodies (MABs). The authors then made recommendations for HPV vaccine administration, and screening using either general population guidelines or increased surveillance, the latter based on following current recommendations for women living with HIV. Additionally, the literature search included antibody response to HPV vaccines and recommendations for their administration for these same conditions.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Based on the reviewed risks, evidence continued to support those persons living with SOT, ESRD, HSCT, and SLE, whether on immunosuppressant therapy or not, had an increased risk of HPV, squamous intraepithelial lesions, and CC whereas there was weak evidence that those persons with IBD, RA, and MS not on immunosuppressants were at risk. Data on persons using DMT/MAB were conflicting. Data showed that patients on certain immunosuppressants had lower antibody titers following HPV vaccination. There were no studies on HPV vaccine efficacy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Following US Center for Disease Control and Prevention HIV Cervical cancer screening (CCS) guidelines is recommended for the following: SOT, ESRD, HSCT, and SLE whether on immunosuppressants or not, and IBD, RA, and MS on immunosuppressants. Shared decision-making about increased surveillance for IBD and RA not on immunosuppressants and persons on any DMT or MAB is reasonable based on conflicting data. Human papillomavirus vaccination should not change the recommendations for increased CC surveillance. A 3-dose series of the HPV vaccine is recommended for all age-eligible patients starting at 9 years of age, with catch-up to 26 years of age. Vaccination from age 27 up to age 45 years per Advisory Committee on Immunization Practices guidelines should be considered in shared decision-making. When possible, HPV vaccine series should be initiated and completed before SOT or initiation of DMT/MAB. For HSCT, the vaccine series should be readministered alon","PeriodicalId":50160,"journal":{"name":"Journal of Lower Genital Tract Disease","volume":" ","pages":"168-179"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11939099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142973068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Lower Genital Tract Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1